US12612392B2: ISR Pathway, eIF2B Heterocyclic Compounds Patent Granted
Summary
The USPTO granted patent US12612392B2 to Shenzhen Zhongge Biological Technology Co., Ltd. on April 28, 2026, covering heterocyclic compounds designed to reduce cellular integrated stress response (ISR) and activate eIF2B activity. The patented compounds aim to enable normal cellular protein synthesis for treating ISR pathway-mediated diseases and eIF2B-related conditions. The patent includes 4 claims and covers the compound structure, pharmaceutical compositions, synthesis methods, and therapeutic applications.
“The present application provides a compound as shown in formula (0), a pharmaceutical composition containing same, a synthesis method therefore and a use thereof.”
About this source
Granted patents in USPTO classification C07D, covering heterocyclic organic compounds: the chemical core of most small-molecule drugs. Around 160 grants a month. Unlike applications, grants are enforceable. This feed is the best public-domain signal of which small-molecule compositions have just become defensible IP, which matters for generic entry timing, freedom-to-operate opinions, and competitive intelligence. Watch this if you practice pharma IP law, manage a drug discovery patent portfolio, advise on compound licensing, or scout ANDA opportunities as brand drugs approach loss of exclusivity. Recent grants cover apalutamide process improvements and bioactive phenolate ionic complexes.
What changed
The USPTO issued patent US12612392B2 to Shenzhen Zhongge Biological Technology Co., Ltd., covering novel heterocyclic compounds of formula (0), pharmaceutical compositions containing them, their synthesis methods, and use for treating diseases related to the ISR pathway and eIF2B activity regulation.
Pharmaceutical and biotechnology companies developing treatments targeting integrated stress response pathways or eIF2B modulation should review this patent to assess freedom-to-operate considerations. The 4-claim scope covers compound compositions and methods for ISR reduction and eIF2B activation in drug development contexts.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Compound, pharmaceutical compositions containing same, synthesis method therefor and use thereof
Grant US12612392B2 Kind: B2 Apr 28, 2026
Assignee
SHENZHEN ZHONGGE BIOLOGICAL TECHNOLOGY CO., LTD.
Inventors
Bin Cao, Liyu Zhao, Guosheng Dou, Sizhu Lu, Dewei Xie
Abstract
The present application provides a compound as shown in formula (0), a pharmaceutical composition containing same, a synthesis method therefore and a use thereof. The compound of the present application can significantly reduce the integrated stress response (ISR) of cells and activate the activity of eIF2B, so that the protein in the cells tends to be synthesized normally, providing more possible drugs for ISR pathway-mediated diseases or condition eIF2B-related diseases, and/or diseases related to regulation of the activity or level of eIF2B activity or level, and regulation of the activity or level of the eIF2 pathway or ISR pathway.
CPC Classifications
C07D 401/06 C07D 413/04 A61K 31/422
Filing Date
2025-07-07
Application No.
19261393
Claims
4
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.